MS
MRVI icon

Maven Securities’s Maravai LifeSciences MRVI Stock Holding History

Maven Securities’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,302
Closed -$221K – 1222
2021
Q1 		$221K Sell
6,302
-76,511
-92% -$2.53M 0.01% 898
2020
Q4 		$2.32M Buy
+82,813
New +$2.31M 0.23% 108

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Maven Securities's MRVI Position: Q2 2021 in Review

Maven Securities sold out of Maravai LifeSciences (MRVI) in Q2 2021, closing a stake of 6,302 shares — an estimated $221K sold.

Maven Securities first reported a position in MRVI in Q4 2020 and held it in 2 quarters. The position peaked at $2.32M in Q4 2020. 196 funds tracked by Wall St. Rank hold MRVI as of Q2 2021.

  • Maven Securities reported no remaining Maravai LifeSciences position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 6,302 Maravai LifeSciences shares in Q2 2021, an estimated $221K.
  • Maven Securities first reported a position in Maravai LifeSciences in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Maravai LifeSciences position peaked at $2.32M in Q4 2020.
  • 196 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.